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Abstract. The Receptor for Advanced Glycation End Products (RAGE) is a multiligand member of the immunoglobulin super-
family. RAGE interacts with AGEs, the products of nonenzymatic glycation/oxidation of proteins and lipids that accumulate in
diverse settings, such as diabetes, inflammation, renal failure, pro-oxidant states and natural aging. In addition, RAGE is also
a receptor for amyloid-β peptide andβ-sheet fibril species. Recent studies underscore the premise that RAGE interacts with
pro-inflammatory molecules, including S100/calgranulins and amphoterin, the latter also known as high mobility group box 1
(HMGB1). In chronic neurodegenerative disorders as well as in nerve tissue upon acute injury, evidence points to upregulation
of both RAGE and these ligand families. In this review, we will discuss the implications of transient/self-limited upregulation
of RAGE and its ligands, vs sustained/chronic upregulation of this axis in neurodegeneration vs repair in both the central and
peripheral nervous systems. Experimental evidence supports the premise that RAGE bears both homeostatic and injurious
properties in the nervous system, thereby highlighting “yin/yang” features of this receptor and its ligand families.
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1. Introduction
The Receptor for Advanced Glycation Endproducts
(RAGE) is a multiligand member of the immunoglob-
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ulin superfamily [36,53]. RAGE was first identified as
a signal transduction receptor for Advanced Glycation
Endproducts (AGEs), the products of nonenzymatic
glycation and oxidation of proteins and lipids, species
that accumulate in a broad array of disease states, such
as diabetes, renal failure, inflammation, neurodegener-
ative disorders such as Alzheimer’s disease and amy-
otrophic lateral sclerosis (ALS), and natural aging [1,5,
6,11,15,18,25–27,42,51,55,61,67]. AGEs may impart
diverse consequences in the tissues via RAGE. Engage-
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ment of RAGE by AGEs may activate multiple signal
transduction pathways in diverse cell types; processes
that may dramatically modulate cellular properties.
Studies have indicated that RAGE also interacts with
distinct molecules beyondAGEs, including amphoterin
(also known as high mobility group box 1 (HMGB1),
S100/calgranulins, amyloid beta peptide (Aβ) andβ-
sheet fibrils, and, most recently, Mac-1 [8,22,24,66,
69]. From this perspective, our data lead us to hypoth-
esize that these families of ligands, at least in part via
RAGE, may exacerbate injury in states of chronic and
unremitting ligand/RAGE expression;and, as well, me-
diate repair when expressed in a transient/self-limited
manner upon acute stress or injury. In this review, we
will discuss the biology of RAGE and present evidence
to suggest that RAGE may contribute to either tissue-
destructive or reparative mechanisms in the injured ner-
vous system.
2. RAGE: first identified as a Receptor for
Advanced Glycation Endproducts (AGEs)
RAGE was first identified as a receptor for AGEs.
AGEs are biochemical modifications of proteins and
lipids that accumulate in multiple states, such as in
hyperglycemia [36,53]. AGEs bound RAGE on key
cell types integral to diabetic complications, including
endothelial cells (EC), mononuclear phagocytes (MP)
and vascular smooth muscle cells (SMC) [28,47,52,
54]. Although AGEs are a heterogeneous group of
modifications, specific AGEs that bound RAGE were
identified, most notably carboxymethyl lysine (CML)
AGE adducts [28].
In diabetic lesions, both in human and experimen-
tal models, AGEs were found at higher levels com-
pared to non-diabetic tissues susceptible to complica-
tions [29,60,65]. In parallel with increased accumula-
tion of AGEs, expression of RAGE was upregulated in
diabetic tissues [12,29,60,65]. To determine if upregu-
lation of RAGE and AGEs in diabetic tissues was linked
to the pathogenesis of complications and tissue injury,
mouse or rat models of diabetic complications were
developed and animals treated with soluble (sRAGE),
the extracellular ligand binding domain of RAGE that
acts as a decoy to bind ligands and prevent their ac-
cess to, and activation of, the cell surface receptor [39].
Using sRAGE, we demonstrated that blockade of the
ligand/RAGE axis suppressed accelerated atheroscle-
rosis in diabetic apolipoprotein E null mice [7,29,39];
improved wound healing in diabetic db/db mice [19];
reversed diabetic vascular hyperpermeability [64]; sup-
pressed albuminuria and mesangial expansion in db/db
mice [65]; diminished alveolar bone loss in diabetic
mice infected with the periodontal pathogenPorphy-
romonas gingivalis [31]; and significantly attenuated
exaggerated neointimal expansion triggered by carotid
artery balloon injury in diabetic rats [70].
These studies were the first to suggest that blockade
of RAGE was associated with beneficial effects in tis-
sues displaying chronic and sustained upregulation of
both RAGE and its ligands.
A key facet of these studies was the demonstra-
tion that diabetic tissues displayed increased expres-
sion of inflammatory and tissue-destructive mediators
compared to non-diabetic tissue. For example, diabetic
skin wounds, periodontium and atherosclerotic plaques
exhibited increased expression of deleterious cytokines
and activation of matrix metalloproteinases (MMPs); in
the presence of sRAGE, in parallel with decreased tis-
sue injury, levels of such mediators were significantly
reduced [7,19,31]. These data strongly suggested that
RAGE was importantly involved in amplification of
inflammatory mechanisms and led us to consider the
question – were AGEs the sole ligands for RAGE?
3. S100/calgranulins and amphoterin:
proinflammatory ligands of RAGE
In-depth investigation into non-AGE ligands of
RAGE led to the identification of two molecule fam-
ilies, S100/calgranulins and amphoterin (HMGB1) as
ligands for RAGE. The link between these molecules
and inflammation transcended RAGE biology from dia-
betic complications to settings more broadly associated
with inflammatory mechanisms.
3.1. S100/calgranulins
S100/calgranulins, a family of at least 20 polypep-
tide members, are characterized by EF hand, calcium-
binding domains. S100/calgranulins may be expressed
by a diverse array of cell types. In the specific context
of inflammation and RAGE, S100/calgranulins may be
produced and released by polymorphonuclear leuko-
cytes, dendritic cells, MP and lymphocytes [16,50,71].
The first S100/calgranulin identified as a signal trans-
duction ligand for RAGE on cells such as EC, SMC,
MP and lymphocytes, was S100A12 (calgranulin C or
Extracellular Newly-identified RAGE binding protein,
EN-RAGE) [22]. In addition, S100s such as S100B
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also bind RAGE; S100B is linked to nervous system
stress [22]. Other S100s, such as S100P, are linked
to key properties in transformed cells. In this context,
RAGE-dependent ligation of S100P increases the pro-
liferation and survival of cancer cellsin vitro [4].
The direct evidence linking RAGE to the euglycemic
inflammatory response was obtained from the follow-
ing experiments. Blockade of RAGE suppressed de-
layed type hypersensitivity in euglycemic mice sensi-
tized and challenged with methylated bovine serum al-
bumin [22]. In other studies, treatment with sRAGE
resulted in decreased colonic inflammation, and activa-
tion of NF-kB in euglycemic IL-10 deficient mice [22].
Blockade of RAGE suppressed joint inflammation and
destruction in DBA/1 mice sensitized/challenged with
bovine type II collagen [23]. In later studies, RAGE
blockade, using pharmacologic approaches and trans-
genic mice expressing signal transduction deficient
RAGE in CD4+ T cells suppressed experimental au-
toimmune encephalomyelitis (EAE) in mice exposed to
encephalitogenic T cells or myelin basic protein [68].
In studies in EAE, the observation that administration
of sRAGE to mice that spontaneously-developed EAE,
that is, mice devoid of endogenous TCR-alpha and
TCR-beta chains, suggested that RAGE was impor-
tantly involved in effector mechanisms that modulate
T cell infiltration into the CNS [68].
Recent studies in a model of adoptive transfer of di-
abetogenic spleen cells into NOD/scid mice have sug-
gested that RAGE may play important roles at more
proximal steps in the immune response [9]. RAGE and
S100 were expressed on islet cells with an inflammatory
infiltrate in pancreata from diabetic NOD/scid mice that
had received a transfer of diabetogenic splenocytes,
but not from control NOD/scid mice. RAGE was ex-
pressed in endocrine cells, as well as in a population
of T cells (CD4+ and CD8+) and B cells in the in-
flamed islets [9]. Treatment with sRAGE significantly
reduced the rate of transfer of diabetes in this model, as
demonstrated by a striking delay in the development of
hyperglycemia. In parallel, the expression of destruc-
tive cytokines, IL-1beta and TNF-alpha, was signifi-
cantly reduced in the sRAGE-treated islets compared
with vehicle-treated animals, in parallel with upregu-
lation of anti-inflammatory cytokines IL-10 and TGF-
beta [9]. However, when the preactivated CD4+ T
cell clone, BDC2.5 cells, was injected into mice, there
was no impact of sRAGE on the development of hy-
perglycemia [9]. Such findings suggested that RAGE
might be implicated in key aspects of T cell activa-
tion. Studies are underway at this time to elucidate the
precise mechanisms underlying these findings.
Studies by Kevin Tracey’s group elucidated that
another RAGE ligand, amphoterin (or high mobility
group box 1 (HMGB1)), displayed proinflammatory
properties.
3.2. Amphoterin
Amphoterin was first identified within the cell as a
DNA binding protein in the nucleus. In addition, it is
well described that amphoterin may also exist extracel-
lularly and on the surface of cells, especially cells ac-
tively migrating [41]. Studies from our laboratory have
explored this molecule’s interaction with RAGE in the
context of neurite outgrowthand tumors [24,59]. As in-
troduced above, Tracey and colleagues first thrust am-
photerin directly into mechanisms linked directly to the
inflammatory response. Like S100/calgranulins, am-
photerin may be released from activated MPs, thereby
leading to propagation of inflammatory responses [2,
63]. Key and direct roles for amphoterin in augmenting
deleterious inflammatory responses were shown by ad-
ministration of blocking antibodies to amphoterin gen-
erated by these investigators. Administration of these
blocking antibodies to amphoterin enhanced survival
of rodents subjected to conditions mimicking that of
overwhelming septic shock [63]. It is important to note
that studies suggest that amphoterin may also interact
with other receptors, specifically toll-like receptor-4
and toll-like receptor 2 (TLR-4 and TLR-2) [38]. Al-
though the precise interplay between RAGE and TLRs
in mediating amphoterin signaling is yet to be fully
uncovered, recent studies suggest that in amphoterin-
enriched environments, such as arthritis, RAGE block-
ade plays important roles [23,40].
Taken together, these considerations strongly sup-
port the premise that RAGE activation in diabetes and
immune-inflammatory states mediates chronic pertur-
bation and injury. Thus, blockade of the receptor af-
forded benefit in such settings. Recent studies on
RAGE and the nervous system demonstrate, however,
that, not surprisingly, this paradigm may not be so
straightforward.
4. RAGE & the CNS: Roles for amplification of
amyloid-beta peptide (Aβ) toxicity
4.1. RAGE is a receptor for Aβ: Evidence from
mouse models of Alzheimer’s disease (AD)
Aβ contributes importantly to the pathogenesis of
neuronal dysfunction in AD. Our first studies demon-
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strated that RAGE bound Aβ in a dose-dependent and
saturable manner, comparable to that of other ligands
for the receptor [66]. Evidence suggestive of roles
for RAGE in AD was elucidated by the enhanced ex-
pression of RAGE in AD brain vs that of age-matched
controls [33,66]. RAGE expression was not limited to
neurons in AD brain, but, as well, included increased
expression in microglia. Importantly, studies also in-
dicated that distinct RAGE ligands, AGEs, were also
enhanced in AD brain [18,67]. Due to the chronicity of
ligand/RAGE accumulation and expression in human
AD and in mouse models, we tested the premise that
such chronic upregulation of this axis mediated sus-
tained perturbation and, thus, enhancement of neuronal
stress.
To directly test this concept, we employed transgenic
mice expressing both mutant amyloid precursor pro-
tein (mAPP) and functional RAGE in neurons. In the
latter case, we employed the PDGF-B chain promoter
to direct expression of full-length functional RAGE to
neurons. As a first test of RAGE-dependent augmen-
tation of stress in the brain, we examined activation
of NF-kB in nuclear extracts prepared from wild-type,
single transgenic (tg) mAPP, single transgenic PDGF
RAGE, and double tg (mAPP/PDGF RAGE) mice. We
found that activation of NF-kB in the brains of double
tg mice was evident at 3–4 months of age, well before
single tg mAPP mice displayed evidence of such acti-
vation [3]. Based on these findings, we subsequently
tested the impact of simultaneous expression of RAGE
and mAPP on key facets of neuronal function.
First, we assessed spatial learning/memory in the
radial arm water maze. Although at 3–4 months of
age, non-tg, tg mAPP, and tg PDGF RAGE mice dis-
played strong learning and memory capacity, double tg
(mAPP/PDGF RAGE) mice displayed increased num-
bers of errors in this test, indicative of impaired spatial
memory for platform location between trials [3]. Fur-
thermore, synaptic transmission under basal conditions
and during long-term potentiation (LTP) were also ex-
amined. Basal synaptic transmission (BST) impair-
ment was accelerated in the double vs single tg mice;
further, only the double tg mice displayed any evidence
of impaired LTP (at 8–9 months of age). In contrast,
single tg (mAPP or PDGF RAGE mice) failed to show
evidence of altered LTP over this time period [3]. Such
findings strongly support the premise that overexpres-
sion of RAGE in an Aβ-enriched environment ampli-
fies perturbation of synaptic function in older mice,
thus impairing plasticity.
Neuropathological studies further supported key
roles for RAGE in augmenting Aβ-toxicity in the brains
of these mice. We examined both acetylcholinesterase
(AchE) activity-positive neurites (predominantly ex-
press cholinergic neurites) and synaptophysin (marker
of presynaptic terminals) in the subiculum, CA1 and
entorhinal cortex. At 3–4 months of age, evidence
of accelerated neuropathological changes was demon-
strated using both markers in double tg mice vs sin-
gle tg mice or wild-type animals [3]. Importantly,
our findings were extended to definitively ascribe roles
for RAGE signaling in transducing the effects of Aβ,
as transgenic mice expressing signal transduction defi-
cient mutants of RAGE in neurons (using the PDGF-B
chain promoter) bred into the mAPP background and
studied at age 3–4 months displayed decreased acti-
vation of NF-kB in nuclear extracts, and strong spa-
tial memory/learning [3]. Further, at later ages, neuro-
logical abnormalities (area occupied by AchE-positive
neurites in the subiculum) were largely prevented in tg
mAPP/PDGF DN RAGE mice compared with tg mAPP
mice.
Taken together, these data strongly support roles for
RAGE/RAGE signaling in mediating, at least in part,
the adverse impact of Aβ in the brain triggered by the
mAPP transgene [3]. Other studies have suggested key
roles for RAGE in Aβ-transport across the blood-brain
barrier (BBB).
4.2. RAGE, Aβ, and transport across the BBB
The impact of Aβ in the CNS is importantly mod-
ulated by interactions with the vasculature, as well as
directly with neuronal and microglial cellular elements.
Systemic Aβ infusion and studies in genetically-
manipulated mice demonstrated that Aβ-RAGE inter-
action in cells of the vessel wall is essential for trans-
port of Aβ across the BBB and influx into the CNS.
Aβ-RAGE interaction in the vasculature results in up-
regulation of inflammatory cytokines and endothelin-1
(ET-1), mechanisms that induce vasoconstriction [13].
Consistent with key roles for RAGE in these processes,
in a mouse transgenic model, inhibition of ligand-
RAGE interaction suppressed accumulation of Aβ in
brain parenchyma [13]. Thus, evidence strongly sup-
ports the premise that Aβ-RAGE is an important mech-
anism by which influx of Aβ into the CNS occurs.
Importantly, the precise balance between Aβ influx-
and efflux-mediating pathways, the latter specifically
effected by low density lipoprotein receptor related
protein-1 (LRP) in the CNS, is likely a critical gate-
way for design of optimal therapeutic interventions in
AD [14]. Such efforts may be impacted upon by the ob-
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servation that blocking RAGE on cultured EC, employ-
ing anti-RAGE IgG, results in upregulation of LRP ex-
pression, as illustrated by Western blotting [14]. These
experiments underscore the possibility that the regula-
tion and/or activities of RAGE and LRP may be linked.
4.3. RAGE, Aβ, AGEs antibodies in AD brain
Evidence from immunological studies is mounting
to support Aβ-RAGE interactionin vivo. Mruthinti
and colleagues showed that plasma samples from AD
subjects displayed significantly higher titers of anti-
bodies directed against Aβ, β-amyloid precursor pro-
tein (β-APP) and RAGE relative to controls without
AD [34]. Other studies have suggested that in astro-
cytes in AD brain, epitopes for AGE, Aβ and RAGE
co-localize [49]. Such findings do not specify cause
and/or effect, however, they establish that these poten-
tially key participants in the pathogenesis and progres-
sion of AD are in the right place and at the right time
to contribute to cellular perturbation, from neurons to
vascular cells and astrocytes.
Such findings also support the view that the biology
of RAGE is not as simple as “one ligand – one disease
process.” Specifically, in the context of AD, it has been
shown that when antibodies to glycated human brain
neurofilament protein (HNF-AGE) were injected into
mice, the animals unexpectedlydeveloped IgGs against
a peptide immunogenic fragment of RAGE and against
human Aβ [35]. These observations suggest that the
time-dependent formation of AGEs may play a role
by modulating expression of Aβ-binding sites, such
as RAGE and, thereby, possibly enhance the cellular
toxicity of these species.
Taken together, these considerations indicate that
both direct (cell surface binding) and immunogenicity
properties of AGE, Aβ, and RAGE, alone or together,
may contribute to cellular perturbation and toxicity in
AD.
5. RAGE & other forms of chronic CNS stress &
neurodegeneration
Pilot studies suggest roles for RAGE in mediating
other forms of neurodegeneration in the CNS. Based
on evidence that AGEs are enhanced in the spinal cord
of human and experimental ALS [11,27,55], studies
have been initiated to begin to test these premises. Em-
ploying mutant SOD1 (G93A) mice, we have found
that overexpression of either neuronal RAGE (using
the PDGF-B chain promoter) or microglial RAGE (us-
ing the scavenger receptor type A promoter) amplifies
neuronal stress in the spinal cord of these animals [43,
46]. Further studies are ongoing to dissect the precise
mechanisms underlying these findings, and to test the
impact of genetic deletion of RAGE, or, alternatively,
abrogation of RAGE signaling in neurons or microglia.
In another chronic neurodegenerative disease, Hunt-
ington’s Disease (HD), selective neuron loss occurs
in the striatum and cortex. Recent studies suggested
that RAGE was expressed in at least two cell types in
the caudate nucleus, medium spiny projection neurons
and astrocytes [32]. Although the increase in RAGE
immunostaining was associated with the increase in
pathological grade of HD, no mechanistic link between
RAGE and pathogenesis/progression of HD has yet
been demonstrated.
Further, in one of the prion diseases, Creutzfeldt-
Jakob disease (CJD), increased numbers of GFAP-
positive astrocytes in the occipital cortex were reported
to be immunopositive for prion protein, AGE epitopes
and RAGE antigen. Astrocytes also were found to con-
tain many AGE- and RAGE-immunopositive granules
which displayed the characteristic pattern of prion pro-
tein expression [48]. Although such findings are not
surprising given that RAGE has been found to bind
β-sheet fibrils, the specific link between ligand/RAGE
expression and CJD is yet to be elucidated and, thus,
requires further study.
6. RAGE & the Peripheral Nervous System: Key
roles in chronic stress
In addition to amyloid-type diseases of the CNS,
amyloid diseases of the PNS also bear a RAGE
link. For example, familial amyloid polyneuropathy
(FAP) is a hereditary amyloidosis induced by mutated
transthyretin which displays proclivity for PNS dys-
function. In FAP, studies have shown that transthyretin
(TTR) is the main protein constituent of amyloid de-
posits in this disorder. Sousa and co-workers first iden-
tified that RAGE expression was increased in FAP tis-
sues in the PNS [58]. In addition, increased activated
NF-kB was also evident in these tissues, as demon-
strated by increased nuclear translocation of p50. In
parallel,in vitro, these investigators showed that RAGE
bound TTR aggregates in cultured PC12 cells and stim-
ulated increased activation of NF-kB. This process was
dependent on RAGE, as indicated by blockade of these
pathways in the presence of anti-RAGE IgG in RAGE-
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expressing Chinese Hamster Ovary cells stimulated
with TTR [57,58].
In addition to PNS amyloidoses, other studies
have placed RAGE and its ligands in vasculitic neu-
ropathies [21]. RAGE, CML-AGEs, NF-kB and IL-
6 were localized in mononuclear cells, epineurial and
endoneurial vessels and perineurium in sural biopsies
of 12 human subjects with vasculitic neuropathies. In
these studies, CML-AGE, RAGE, NF-kB and IL-6
were expressed by CD4+ and CD8+ T cells, as well
as CD68+ MP invading the peripheral nerve [21].
Thus, evidence for augmentation of stress, in part
via RAGE, in the CNS and PNS has been suggested
in these chronic neurodegenerativedisorders character-
ized, in part, by sustained upregulation of RAGE and
its ligands. In this context, it thus became important to
test the impact of RAGE in acute injury in the nervous
system. From studies in the PNS, unexpected findings
emerged from these experiments that highlighted for
the first time innate roles for RAGE in restoration of
homeostasis after acute injury.
7. RAGE & the PNS: Key roles in repair after
acute injury
To delineate roles for RAGE in acute injury in the
PNS, we employed a murine model of experimental ax-
otomy. It is established that axotomy induced by nerve
transection or crush activates an integrated series of cel-
lular responses that mediate sharp but limited periods
of inflammation that facilitate removal of myelin debris
and damaged axonal elements distal to the site of injury
(collectively termed “Wallerian degeneration).” In par-
allel, injury also triggers sprouting and elongationof re-
generating axons as they grow from the proximal nerve
stump into the distal stump in an attempt to reinnervate
target tissue and, thus, potentially restore function [17,
30]. Effective Wallerian degeneration is essential for
optimal axonal outgrowth and regeneration.
Since key roles for RAGE in inflammatory mech-
anisms were established in a distinct array of im-
mune/inflammatory settings, even beyond hypergly-
cemia, it was thus logical to determine if RAGE and its
ligands contributed to PNS repair triggered by acute ax-
otomy. These studies were performed in non-diabetic
mice. Both at baseline and at 18 hrs after unilateral
crush of the sciatic nerve in C57BL/6 mice, segments
within the first 3 mm distal to the site of crush dis-
played expression of RAGE in axons, as elucidated by
colocalization with anti-neurofilament IgG [44]. At 18
hours after crush, RAGE was also expressed in MP in
the distal segments, as shown by coexpression of im-
munoreactive RAGE and CD 68 [44]. Thus, RAGE
was expressed in two important cell types linked to pe-
ripheral nerve regeneration, inflammatory MP and pe-
ripheral neurons. Importantly, these studies also eluci-
dated that S100/calgranulins and amphoterin were also
increased in the distal segments after crush in wild-
type mice; importantly, by 21 days after crush, levels
of these molecules began to return to those observed in
homeostatic, uninjured states.
Based on these findings, we first employed phar-
macological blockade of RAGE to test the impact of
RAGE in peripheral nerve regeneration. Mice received
either sRAGE or vehicle,murine serum albumin (MSA)
or PBS. Compared to control treatment,sRAGE-treated
animals displayed significantly decreased motor and
sensory nerve conduction velocities on day 21 after
crush, in parallel with diminished gait in a walking track
analysis [44]. Definitive evidence of impaired regen-
eration was evident upon examination of myelinated
fibers. In sRAGE-treated animals, decreased myeli-
nated fiber density was noted compared to control-
treated animals [44]. Additional strategies to test the
role of RAGE and its ligands including the adminis-
tration of blocking F(ab’)2 fragments prepared from
anti-RAGE or anti-ligand (S100/calgranulin and am-
photerin) IgG. Compared to non-immune F(ab’)2 frag-
ments, treatment of mice with F(ab’)2 fragments de-
rived from anti-RAGE, anti-S100/calgranulin or anti-
amphoterin IgG resulted in decreased functional and
morphological evidence of regeneration after sciatic
nerve crush [44].
Although pharmacological blockade of RAGE im-
peded regeneration triggered by crush, these studies
did not elucidate if the primary impact was on MP
RAGE and/or axonal RAGE. To test these specific con-
cepts, we employed non-diabetic mice expressing sig-
nal transduction deficient RAGE in either MP (using
the scavenger receptor type A promoter) or peripheral
neurons (using a fragment of the thy-1 promoter).
First, we studied the impact of RAGE signaling in
MP. In tg mice expressing dominant negative (DN)
RAGE in MP, on day 3 after crush, numbers of MP in
the distal segments were significantly diminished com-
pared to wild-type littermates [45]. Phosphorylation
of p44/p42 MAP kinase was significantly reduced in
the distal nerve segments at 18 hours in transgenic ver-
sus littermate mice, as well. To determine the effect
of deficient RAGE signaling in peripheral neurons, we
subjected tg mice to sciatic nerve crush. Levels of
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phospho-p44/p42 MAP kinases were decreased 18 hrs
after injury in distal segments in transgenic versus lit-
termate animals [45]. Levels of phospho-STAT3 were
significantly reduced on day 7 in the distal segments of
sciatic nerve in transgenic thy-1 DN-RAGE mice com-
pared to littermates [45]. These experiments elucidated
that modulation of key signaling pathways linked to
PNS regeneration were modulated by RAGE signaling.
To determine if such changes in RAGE signaling
contributed to alterations in regeneration triggered by
injury, nerve crush was then performed in single or
double tg mice. Compared to wild type littermate
mice, transgenic mice expressing DN RAGE in MP
displayed an≈ 40% and≈ 45% decrease in motor
and sensory nerve conduction velocities on day 21 af-
ter crush [45]. Compared to wild-type littermate mice,
transgenic mice expressing DN RAGE in peripheral
neurons displayed an≈ 39% and≈ 37% decrease
in motor and sensory nerve conduction velocities on
day 21 [45]. Simultaneous expression of DN RAGE in
mononuclear phagocytes and neurons further exacer-
bated functional recovery after crush, as double trans-
genic mice displayed an≈ 85% reduction in motor and
sensory nerve conduction velocities on day 21 com-
pared to wild-type controls, and an≈ 70% decrease
in motor and sensory nerve conduction velocities com-
pared to single transgenic mice expressing DN RAGE
in either MP or peripheral neurons [45].
Quantitative analyses of semithin sections demon-
strated that mice expressing DN RAGE in MP (single
or double transgenic) displayed increased myelin de-
bris compared to wild-type mice, and mice express-
ing DN RAGE in neurons alone displayed increased
myelin debris compared to wild-type mice [45]. Fur-
ther, myelinated fiber density was significantly reduced
by ≈ 42% in mice carrying the DN RAGE transgene
in either MP or neurons compared to control litter-
mates [45]. Mice expressing DN RAGE in both MP
and neurons contained≈ 67% less myelinated fibers in
the sciatic nerve distal segments than wild-type mice,
and≈ 43% less myelinated fibers than single trans-
genic animals expressing DN RAGE in either MP or
peripheral neurons [45].
These findings highlighted for the first time innate
roles for RAGE in both inflammatory Wallerian de-
generation and axonal outgrowth consequent to acute
crush in the peripheral nerve. In the absence of dia-
betes, we posit that acute crush stimulates rapid and
sharply-limited expression of RAGE and its ligands,
S100/calgranulins and amphoterin that contribute, to-
gether, to mediating essential inflammatory mecha-
nisms that remove myelin debris, and mechanisms that
support axonal outgrowth.
In the context of peripheral nerve repair, it has been
suggested that PNS injury triggers processes that re-
capitulate, in part, developmental mechanisms [37].
What is the evidence linking the ligand-RAGE axis to
developmental programs?
8. The ligand-RAGE axis and development
Expression of RAGE is enhanced in developing
CNS neurons and falls in the immediate post-natal pe-
riod [24]. Studies have illustrated that at least two of
RAGE’s ligands, S100b and amphoterin, are expressed
in developing brain where they may play roles as neu-
rotropic, neuronal survival proteins, as well proteins
involved in modulating neurite outgrowth and cell mi-
gration [10,20,62]. Importantly, studies in homozy-
gous RAGE null mice do not support critical roles for
this receptor in neuronal development, as RAGE null
mice are viable and display normal reproductive ca-
pacity and growth [47]. However, it is possible that
activation or upregulation or compensatory pathways
have masked essential roles for RAGE in the process
of development.
Although roles for RAGE in PNS development have
been less well studied, it is notable that peripheral
nerves appear to develop normally in RAGE null mice,
and in transgenic mice expressing DN RAGE in neu-
rons [45]. In the adult mouse, however, disruption
of neuronal RAGE signaling in the latter mouse, sup-
pressed optimal axonal regeneration following crush
injury. In this context, evidence is emerging that sig-
naling pathways linked to development vs the (adult)
response to neuronal injury are distinct [56], based
on divergent signal transduction responses via STAT3
and MAP kinases [56]. Thus, it is not surprising that
RAGE-dependent developmental vs adult response-to-
injury paradigms may, indeed, differ greatly.
9. RAGE, diabetes and the PNS: Impact of acute
stress
Although our studies have addressed the role of
RAGE in chronic diabetes and neuropathy, these find-
ings raise the important question, what is the role
of RAGE in acute injury in the diabetic peripheral
nerve? Does RAGE mediate deleterious and/or bene-
ficial mechanisms in such a setting? We posit that in
362 L.L. Rong et al. / RAGE, peripheral nervous system, central nervous system
Fig. 1. RAGE: “Yin/Yang” in the Nervous System. Experimental evidence supports roles for RAGE-amplified injury and failure of restorative
mechanisms in settings characterized by chronic upregulation of the ligand-RAGE axis, such as in long-standing diabetes, inflammation and
neurodegenerative disorders, such as Alzheimer’s disease. In contrast, in acute stress, such as that triggered by peripheral nerve crush in
euglycemia, evidence supports the contention that transient and sharply-limited upregulation of the ligand-RAGE axis may contribute, in part,
to repair and restoration of homeostasis. These findings elucidate the novel concept that RAGE, indeed, possesses key and innate functions. In
future application of RAGE blockade in chronic disease, a fine balance must be struck between RAGE-dependent injurious- and RAGE-dependent
regenerative pathways.
chronic diabetic neuropathy, long-standing accumula-
tion of AGEs and perhaps other inflammatory ligands
will result in chronic upregulation of RAGE. The im-
pact of RAGE on repair mechanisms triggered by acute
injury in chronic diabetes must, therefore, be dissected.
Such studies are underway at this time.
10. Perspective & conclusion: A small dose of
RAGE may be beneficial?
Figure 1 depicts the hypotheses underlying the appar-
ently divergent roles for RAGE in the nervous system.
Our studies suggest that in settings of chronic stress –
whether it be diabetic tissues or the brain in AD – upreg-
ulation of the ligand-RAGE axis contributes critically to
the pathogenesis of neuronal dysfunction and neurode-
generation. The accumulation of protein fragments,
such as Aβ and perhaps AGEs, S100/calgranulins and
amphoterin, within brain parenchyma and vasculature
provides a chronically modified template in which
homeostatic and reparative processes are sharply cur-
tailed, at least in part, via RAGE. In stark contrast, in
peripheral nerve, at least certain of these same cofac-
tors, such as S100/calgranulins,amphoterin and RAGE,
ignite essential mechanisms that augur effective in-
flammation and axonal outgrowth in repair pathways.
Precisely how these same cofactors may have a piv-
otal role in innate, neuroprotective pathways that or-
chestrate reparative processes, versus highly deleteri-
ous neuro-injurious pathways that orchestrate chronic
neurodegeneration, at least in part via RAGE, is the
focus of intense study.
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